Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $28.72M rose 5.4% year over year, ahead of the -25.2% change in trailing-twelve-month research & development. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at -14.7% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.4% holds above the trailing-twelve-month pace of -25.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 107.3M USD
- Year-over-year change
- -36.0%
- 4-year CAGR
- -11.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 107.3M | -36.0% |
| FY2024 | 2024-12-31 | 167.77M | -28.7% |
| FY2023 | 2023-12-31 | 235.16M | +36.1% |
| FY2022 | 2022-12-31 | 172.73M | -1.6% |
| FY2021 | 2021-12-31 | 175.6M | — |
Research & Development vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 research & development of $108.76M is the 3rd highest of the 11 companies compared; the peer median is $69.26M.
- Its year-over-year change of -25.2% is the 7th highest of 11, against a peer median of -15.4%.
- Over three fiscal years its annual growth of -14.7% compares with a peer median of +4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.37M | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M | +115.1% | +40.7% | — |
| LTM Mar 2026 | $79.04M | -54.8% | +4.0% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $71.8M | +27.7% | +16.5% | — |
| LTM Mar 2026 | $66.71M | -38.5% | -7.9% | — | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| LTM Mar 2026 | $36.3M | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $20.26M | +102.3% | +57.1% | — | |
| LTM Mar 2026 | $20.04M | +101.3% | -58.6% | — | |
| Peer median (excluding ZNTL) | $69.26M | -15.4% | +4.8% | 135.2% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 67.43M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 67.43M | 0 |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 175.6M | 172.73M | 235.16M | 167.77M | 107.3M |
| Selling, General & Admin | 40.94M | 54.55M | 59.4M | 87.12M | 37.72M |
| Operating Expenses | 216.54M | 227.29M | 299.51M | 258.62M | 152.81M |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| EBITDA | (207.2M) | (233.58M) | (247.6M) | (186.17M) | (144.27M) |
| EBITDA Margin | — | — | — | -276.1% | — |
| Operating Income | (216.54M) | (227.29M) | (299.51M) | (191.19M) | (152.81M) |
| Operating Margin | — | — | — | -283.6% | — |
| Interest Income | 0 | 2.26K | 0 | 0 | 0 |
| Interest Expense | 0 | 2.58M | 0 | 0 | 0 |
| Other Income / Expenses | 50.15M | (10.3M) | 6.6M | 25.5M | 16.19M |
| Income Before Tax | (166.39M) | (237.58M) | (292.91M) | (165.69M) | (136.62M) |
| Pre-Tax Margin | — | — | — | -245.7% | — |
| Income Tax Expense | (297K) | (469K) | (601K) | 177K | 442K |
| Net Income | (158.73M) | (236.81M) | (292.19M) | (165.84M) | (137.06M) |
| Net Margin | — | — | — | -246.0% | — |
| EPS (Basic) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| EPS (Diluted) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| Weighted Avg Shares | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
| Weighted Avg Shares (Diluted) | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.